Chronic renal failure
Conditions
Interventions
Trade Name: Omegaven
Product Name: Omegaven
Pharmaceutical Form: Emulsion for infusion
Pharmaceutical form of the placebo: Intravenous infusion
Route of administration of the placebo: Intravenous use
Sponsors
Nyremedicinsk afdeling, Aalborg Sygehus
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with chronic renal failure undergoing haemodialysis treatment three times a week Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Allergy to fish or egg protein. Age 3 mmol/L.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the effect of intravenous infusion of an emulsion rich on n-3 polyunsaturated fatty acids on heart rate variability and the occurence of arrhythmias in relation to haemodialysis treatment;Secondary Objective: To determine the content of n-3 polyunsaturated fatty acids in plasma and cell membranes before and after infusion;Primary end point(s): The effect on heart rate variability and arrhythmias | — |
Countries
Denmark
Outcome results
None listed